47.20
전일 마감가:
$45.65
열려 있는:
$45.15
하루 거래량:
5.32M
Relative Volume:
1.87
시가총액:
$115.87B
수익:
$43.23B
순이익/손실:
$6.79B
주가수익비율:
11.75
EPS:
4.0174
순현금흐름:
$9.17B
1주 성능:
+0.68%
1개월 성능:
-4.61%
6개월 성능:
-14.89%
1년 성능:
-18.10%
사노피 ADR Stock (SNY) Company Profile
SNY을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
SNY
Sanofi Adr
|
47.20 | 111.25B | 43.23B | 6.79B | 9.17B | 4.0174 |
![]()
LLY
Lilly Eli Co
|
763.00 | 651.28B | 53.26B | 13.80B | -50.20M | 15.30 |
![]()
JNJ
Johnson Johnson
|
185.42 | 437.40B | 90.62B | 22.66B | 18.18B | 9.35 |
![]()
ABBV
Abbvie Inc
|
231.54 | 394.23B | 58.33B | 3.73B | 18.24B | 2.10 |
![]()
NVS
Novartis Ag Adr
|
128.24 | 240.24B | 53.40B | 13.68B | 16.89B | 6.9231 |
![]()
MRK
Merck Co Inc
|
83.93 | 196.28B | 63.43B | 16.42B | 14.72B | 6.49 |
사노피 ADR Stock (SNY) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-09-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2025-09-02 | 업그레이드 | Deutsche Bank | Hold → Buy |
2025-08-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
2025-03-21 | 개시 | Goldman | Neutral |
2025-01-30 | 업그레이드 | Deutsche Bank | Sell → Hold |
2024-07-26 | 재확인 | Argus | Buy |
2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
2024-01-16 | 재개 | UBS | Buy |
2023-12-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2023-10-30 | 다운그레이드 | Stifel | Buy → Hold |
2023-09-06 | 업그레이드 | Berenberg | Hold → Buy |
2023-07-14 | 개시 | HSBC Securities | Buy |
2023-04-28 | 다운그레이드 | Deutsche Bank | Hold → Sell |
2023-03-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
2022-12-13 | 재개 | Morgan Stanley | Overweight |
2022-08-12 | 업그레이드 | Deutsche Bank | Sell → Hold |
2022-08-09 | 다운그레이드 | UBS | Buy → Neutral |
2022-05-23 | 개시 | SVB Leerink | Outperform |
2021-09-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
2021-01-15 | 개시 | Deutsche Bank | Sell |
2020-09-29 | 개시 | Berenberg | Hold |
2020-03-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
2020-03-11 | 업그레이드 | Goldman | Neutral → Buy |
2020-02-11 | 개시 | SVB Leerink | Mkt Perform |
2020-01-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
2019-09-20 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2019-09-03 | 개시 | Bernstein | Outperform |
2019-08-14 | 업그레이드 | UBS | Neutral → Buy |
2018-12-11 | 업그레이드 | Jefferies | Hold → Buy |
2018-11-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
2018-10-09 | 개시 | Guggenheim | Neutral |
2018-09-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
2018-08-10 | 업그레이드 | Citigroup | Neutral → Buy |
2018-03-23 | 업그레이드 | Liberum | Hold → Buy |
2018-01-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
2017-12-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2017-12-01 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
2017-11-15 | 업그레이드 | Barclays | Underweight → Equal Weight |
2017-08-30 | 업그레이드 | HSBC Securities | Reduce → Hold |
모두보기
사노피 ADR 주식(SNY)의 최신 뉴스
BostInno🗳️ Vote in Inno Madness round two | 💻 UKG announces layoffs - The Business Journals
Sanofi Expands Insulin Savings Program To Cover All US Patients - Benzinga
Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability - Sahm
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit - Sahm
Sanofi: Informations relatives au nombre de droits de vote et d'actions - GlobeNewswire Inc.
Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS® - Ariva
What's Going On With Nektar Therapeutics Stock On Thursday? - Sahm
Why Is Sanofi Stock Falling Thursday? - Sahm
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors - Sahm
New Report Highlights Community Health Workers' Impact, Calls for Sustained Local Investment, During National CHW Awareness Week - Ariva
European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest
Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary - Seeking Alpha
Sanofi ADR (SNY) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Sanofi ADR earnings beat by $0.63, revenue fell short of estimates - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SanofiSNY - cnhinews.com
Sanofi: Reassessing Our Moat Rating for This Leader in Immunology, Vaccines, and Rare Diseases - Morningstar
BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study - Ariva
AstraZeneca pledges $50 bln investment in US as pharma tariffs loom By Investing.com - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SanofiSNY - FinancialContent
Adagene stock gains as Sanofi expands agreement (ADAG:NASDAQ) - Seeking Alpha
사노피 ADR (SNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):